Drugs / REGEND001 Autologous Basal Layer Stem Cell Suspension
REGEND001 Autologous Basal Layer Stem Cell Suspension
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06998706 | Jun 2025 → Jun 2029 expected | interstitial lung disease | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGEND001 Autologous Basal Layer Stem Cell Suspension | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998706 ↗ |
| Modality | Cell therapy | “an innovative cell therapy product” NCT06998706 ↗ |
| Route | Other | “the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments” NCT06998706 ↗ |